Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Netakimab in Chinese Adult Patients With Moderate to Severe Plaque Psoriasis
NCT07008547Phase 3Completed
- Sponsor
- SPH-BIOCAD
- Start
- Jul 2024
- Primary completion
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing Netakimab with Placebo (2 arms). Primary endpoints: Proportion of subjects achieving Psoriasis Area and Severity Index 75 at 12 weeks and Proportion of subjects achieving static Physician's Global Assessment 0 or 1 at 12 weeks. Started Jul 2024; status: completed.
02
Drugs
netakimab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT07008547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07008547.